tirzepatide and semaglutide for weight loss vs. Tirzepatide Outperforms Semaglutide in Blood

CMS has unveiled its BALANCE model, a voluntary Medicare and Medicaid coverage pathway for GLP-1s that includes price negotiations and supplemental lifestyle support, with coverage beginning in 2026 for Medicaid and 2027 for Medicare Part D [2]

The FDA just dropped a 68-page PDF on if BPC-157 should be legal or not to compound

A retrospective study conducted in a Hispanic pediatric population with NAFLD found that BMI and z-scores in children who took antihistamine medications compared to children who were not medicated (Saad et al., 2020)

However, GLP-1 medications are not risk-free

In animal models, GLP-1 enhances myocardial glucose usage, shifting metabolism from fatty acid to carbohydrate oxidation